We recently published 8 Stocks That Jim Cramer Recently Talked About. Novartis AG is one of the stocks Jim Cramer recently discussed.
Novartis AG is a Swiss pharmaceutical company that is one of the largest of its kind. Its shares have gained 17% year-to-date, but the shares lost 2.5% in July after the firm’s fiscal first quarter earnings report. The results saw Novartis AG post $14.05 billion in revenue, which fell short of analyst estimates of $14.18 billion. However, the firm’s operating profit sat at $5.93 billion which was higher than the $5.69 billion that analysts had penciled in. For his part, Cramer had a shocking question on his mind as he wondered whether Novartis AG CEO Dr. Vasant Narasimhan was leaving the company:
“[On NVS raising the guide and getting a buyback]”They did have one failure of a drug, that was very, very important but I saw that Vass, Vass is going? He’s a terrific CEO.”
Updated July 22nd, 2025: Novartis reached out to CNBC and confirmed that Cramer misspoke during the show. A Novartis spokesperson who reached out to Insider Monkey denied that the CEO was leaving and remarked: “Novartis CEO Vas Narasimhan is not leaving the company.”
A doctor holding a microscope in front of a laboratory sample of healthcare products.
Loomis Sayles Global Growth Fund mentioned Novartis AG in its Q1 2025 investor letter. Here is what the firm said:
“Novartis AG (NYSE:NVS) is a diversified global healthcare company with market leadership in branded pharmaceuticals across a broad range of treatment areas, including oncology (30% of revenues), immunology (almost 20% of revenues), cardiovascular, renal, and metabolic (almost 20%), and neurology (10%). The company also derives over 20% of revenues from mature branded products in non-core therapy areas. With the October 2023 spinoff of the company’s Sandoz generics and biosimilars division, which followed the 2019 spinoff of ophthalmologic equipment maker Alcon and 2018 divestiture of a consumer health joint venture, the company is now purely focused on innovative medicines, which accounted for about 80% of revenue and 85% of core operating income prior to the Sandoz spinoff. The company generates over 50% of revenue from the Americas, approximately 30% from Europe, and almost 20% from the rest of the world.”
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
